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Background. IgA nephropathy (IgAN) is characterized by dep-
osition of polymers of IgA1 in the mesangium, accumulation of
mesangial matrix and mesangial cell proliferation. Activation of
the mesangial cell by IgA, via an IgA receptor, may be an
initiating event in the pathology of IgAN.
Methods. We examined the ability of radiolabeled, normal
serum IgA1 to bind human mesangial cells (HMC). Activation of
HMC by monomeric (mIgA1) and heat aggregated IgA1 (AIgA1)
was compared by Northern analysis of c-jun expression. The
expression of FcaR1 (CD89) mRNA on our cultured mesangial
cells was also assessed by Northern analysis, reverse transcription-
polymerase chain reaction (RT-PCR) and flow cytometry.
Results. 125I-mIgA1 and
125I-AIgA1 bound to HMC in a dose-
dependent, saturable manner with similar affinities. There were
1.2 3 106 binding sites per cell, with an affinity constant of 2.3 3
106 M21. AIgA1 induced c-jun expression in a time and dose-
dependent manner (2.4-fold above baseline after 60 min exposure
to AIgA1 200 mg/ml) while mIgA1 had no effect on c-jun
expression. No message for CD 89 was detectable in quiescent or
AIgA1 stimulated HMC by Northern analysis or RT-PCR using
several primer sequences based on the sequence of U937 FcaR
cDNA. Flow cytometry on the mesangial cells, using My 43, a
monoclonal antibody to FcaR1 confirmed that CD 89 was not
present on the cell.
Conclusion. These results demonstrate that HMC bind mIgA1
and AIgA1 with similar affinity. However, activation of HMC
requires an aggregated form of IgA1. These processes are inde-
pendent of FcaR1, suggesting the presence of a new IgA receptor
on mesangial cells.
IgA nephropathy (IgAN) is the most common form of
primary glomerulonephritis in the world [1, 2]. The hall-
mark of the disease is the deposition of IgA isotype 1 in the
glomerular mesangium in proximity to mesangial cells [3,
4]. The histopathology of IgAN is characterized by abun-
dance of mesangial matrix and proliferation of mesangial
cells [5]. Serum polymeric IgA1 (pIgA1) is increased in
patients with IgAN [6–8] and polymeric IgA has been
demonstrated in protein eluates of biopsy specimens from
IgAN patients [9, 10]. One potential pathogenetic scheme
for the development of IgAN is that exposure to certain
environmental antigens, particularly at mucosal surfaces,
increases production of serum polymeric IgA1 or IgA1-
containing immune complexes which have a propensity to
deposit in the glomerular mesangia [11]. IgA1 deposition
might induce mesangial cell proliferation and/or produc-
tion of extracellular matrix. One important aspect of this
hypothesis is the nature of the interaction between IgA and
the mesangial cell.
Recently, it was reported that primary cultures of human
mesangial cells express messenger RNA for Fca receptor 1
(FcaR1) [12, 13], similar to that cloned from the myeloid
precursor cell line U937 [14]. This receptor, designated CD
89 [15], is expressed on human neutrophils, monocytes and
eosinophils [16–18] and binds monomeric, dimeric and
heat aggregated IgA1 (AIgA1) and IgA2 [12, 16]. Exposure
of cultured mesangial cells to high concentrations of IgA1,
Il-6, TNF-a or interferon-gamma enhance expression of
CD 89 mRNA [12, 13].
Incubating mesangial cells with AIgA has multiple early
and late metabolic effects. AIgA stimulates the release
from rat mesangial cells of interleukin-6 (IL-6), TNF-a,
platelet activating factor (PAF), prostaglandin E2 (PGE2),
and superoxide anion [19–22]. The earliest signaling events
in human mesangial cells exposed to AIgA include activa-
tion of phospholipase Cg3 (PLCg3), increase in inositol
phosphate 3 (IP3) and intracellular calcium mobilization
[23]. While these effects are thought to be mediated
through an FcaR, presumably CD 89, blocking of the
effects by a specific antibody against this receptor has not
been reported.
One of the early nuclear events following activation of
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many cell types, including mesangial cells, is induction of
proto-oncogenes such as c-jun and c-fos [24, 25]. The
immediate early gene transcription factor c-Jun binds to
AP-1 sites, as a homodimer or heterodimer with c-Fos, on
many long-term expression genes [26]. Induction of c-jun in
mesangial cells has been linked to cell proliferation and
matrix synthesis [27], although the ultimate functional
outcome also depends on the ligand, receptor and nuclear
signaling [24].
The purpose of the current study was to examine the
effects of various forms of human serum IgA1 on mesangial
cell activation. c-jun induction was chosen as an early
marker of these events. In addition, we sought to determine
if induction of c-jun in our primary cultures of mesangial
cells was mediated by FcaR1 (CD89).
METHODS
Isolation and aggregation of human serum IgA1
IgA1 was isolated from normal human sera by jacalin
affinity chromatography [28]. Whole blood from laboratory
workers was allowed to clot at 25°C for 30 minutes and the
serum was promptly collected by centrifugation and frac-
tionated immediately or stored at 280°C. Serum was
diluted 1:1 with phosphate buffered saline (PBS) pH 7.1,
and then filtered through a 0.2 m Corning syringe filter
(Corning Glass Works, Corning, NY, USA) and applied to
a jacalin column. The columns were prepared using com-
mercially available Jacalin immobilized on cross-linked 6%
beaded agarose (Pierce, #20395; Rockford, IL, USA) with
an IgA1 binding capacity of 1 to 2 mg/ml of gel. The column
was then washed with PBS until the optical density (OD
280) was less than 0.10. IgA1 was eluted, with 0.2 M
melibiose (Sigma, St. Louis, MO, USA) in PBS, in 1 ml
fractions until the optical density returned to 0.1. The
fractions were pooled and then concentrated to approxi-
mately 5 mg/ml by ultrafiltration using 30,000 molecular
weight exclusion membranes (Centriprep 30; Amicon, Bev-
erly, MA, USA). The concentrated sample was dialyzed
against PBS until the melibiose concentration was deter-
mined to be less than 10 nmol/liter. The various molecular
size forms of IgA1 were separated by HPLC molecular
sieve chromatography using a 1.5 3 30 cm Superdex HR
200 column (Pharmacia Biotech, Inc., Piscataway, NJ,
USA) mounted on a Pharmacia Smart System equipped
with a micropeak detector. When 200 ml of the filtered,
concentrated IgA1 was applied to the column three distinct
peaks in the OD280 absorption profile were noted. The
molecular size of each IgA fraction was determined by
SDS-PAGE and Western analysis using HRP-linked rabbit
anti-IgA (Dako, Carpinteria, CA, USA), antibody to hu-
man joining chain (J chain; Biodesign International, Ken-
nebunk, ME, USA) and secretory component (SC; Dako).
A total of 98% of the protein in the third peak migrated
consistent with monomeric IgA on SDS-PAGE and West-
ern blots were strongly positive for alpha chain but dem-
onstrated only a trace of J chain and no SC. The mono-
meric IgA1 (mIgA1) fraction was used to prepare AIgA1
with some modification of the method of Egido et al [29].
The samples of mIgA1 at 2 mg/ml in PBS were passed
through a 0.2 m filter and then heated at 63°C for 150
minutes. The samples were immediately placed on ice and
then micro-centrifuged to remove insoluble precipitant.
The soluble AIgA1 was characterized by molecular sieve
chromatography on the HR 200 column. Approximately
90% of the IgA had a molecular weight of greater than 600
kD.
Isolation and culture of human mesangial cells and U937
cells
A normal portion of human kidney cortex was obtained
from a nephrectomy specimen removed for cystic compli-
cations of previous infection. Primary cultures of human
mesangial cells (HMC) were grown from glomerular ex-
plants as previously described [30]. Briefly, cortical tissue,
bathed in Hank’s balanced salt solution (HBSS) at 4°C, was
minced and sequentially passed through 80, 100, and 150
mesh screens (Sigma). The retained glomeruli were washed
with copious amounts of HBSS to remove tubular frag-
ments, incubated for 30 minutes at 37°C with 500 U/ml
collagenase type IV (Sigma) and centrifuged at 50 3 g for
five minutes at 4°C to pellet the glomeruli. The pelleted
glomeruli were plated in untreated 75-cm2 tissue culture
flasks (Costar, Cambridge, MA, USA) in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (Gibco BRL, Grand Island,
NY, USA) containing 200 mmol/liter L-glutamine supple-
mented with 20% fetal calf serum (FCS), 25 mmol/liter
sodium bicarbonate, penicillin G 100 U/ml, streptomycin
100 mg/ml (Sigma), and human insulin 0.06 U/ml (Eli Lilly
& Co., Indianapolis, IN, USA). Cultures were maintained
in humidified 5% CO2 atmosphere at 37°C. Cells were
passaged when confluent using 0.05% trypsin in 0.53 mM
EDTA. The concentration of FCS was reduced to 10% for
cultures in passes 3 through 5. All stimulation studies were
performed using cells at the fifth passage. Purity and
identification of mesangial cells were by cell morphology,
negative staining by indirect immunofluorescence with an-
tisera to cytokeratin and factor VIII antibody (Sigma), and
positive staining of actin arrays with rhodamine phalloidin
(Molecular Probes, Inc., Eugene, OR, USA). U937 cells
obtained from ATCC (Rockville, MD, USA) were grown in
RPMI 1600 media with 10% FCS (Gibco).
Binding of radiolabled IgA1 to mesangial cells
Human mesangial cells (passages 3 to 6) were thawed
from liquid nitrogen storage, washed once, suspended in
medium, and aliquoted into 24-well tissue culture dishes.
The cells were grown to confluency (about five days) in
DMEM containing 10% FCS, penicillin, streptomycin,
insulin, 28 mM sodium bicarbonate, 10 mM HEPES at pH
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7.35. Cells were washed once in PBS and incubated for 30
minutes in DMEM without serum. The cells were then put
on ice, washed twice with PBS, and incubated for 60
minutes with 125I-IgA (2 mg/ml) in 0.2 ml PBS alone or in
the presence of increasing amounts of nonradioactive IgA
up to 400 mg/ml and asialo orosomucoid (ASOR) up to 100
mg/ml. Monomeric and AIgA1 were radiolabeled with
Na125I (10 to 20 mCi/mg iodine; Amersham corp, Arlington
Heights, IL, USA) [31]. The radioactive medium was
removed and the cells were washed three times with HBSS.
The cells were solubilized in 0.3 N NaOH (0.4 ml) and the
lysates were transferred to gamma tubes and the radioac-
tivity was quantified in a Packard 5002 gamma counter
(Downer’s Grove, IL, USA). The protein content of the
samples was measured by the Bradford method [32] using
BSA as the standard. Determinations were performed in
duplicate and the data were analyzed using the RADLIG
and LIGAND programs of Munson and Rodbard (version
4; BIOSOFT, Ferguson, MO, USA).
Northern analysis of IgA induced c-jun mRNA expression
Human mesangial cells were grown in untreated 25-cm2
flasks (Costar) until confluent. For the evaluation of c-jun
expression, the cells were serum starved in DMEM for 48
hours prior to study. Cells were checked for viability by
phase contrast microscopy ensuring attachment to the
plate. Concentrated IgA1 or the control protein albumin in
500 ml of PBS pH 7.1 was added to each flask containing 2.5
ml of serum free media to attain the desired protein
concentrations in a total volume of 3 ml. Cell viability was
again determined 60 minutes after the addition of the IgA,
just before harvesting the RNA. Total cellular RNA was
isolated by the single step method described by Chomczyn-
ski and Sacchi [33]. Twenty micrograms of total RNA was
separated on a 1% agarose gel with 1.1 M formaldehyde and
transferred overnight onto a nylon membrane (MSI Corp.,
Westborough, MA, USA). The full length cDNA probe for
c-jun was obtained from ATCC (Rockville, MD, USA) and
radiolabeled with [32P]dCTP by random priming (NEBlot;
New England Biolabs, Beverly, MA, USA). Hybridization
was performed overnight at 42°C in a standard solution as
previously described [34]. The membranes were washed in
5 3 SSPE for 30 minutes at room temperature, 1 3 SSPE
for 30 minutes at 37°C and 0.1 3 SSPE for 45 minutes at
65°C. The blots were autoradiographed using Kodak X-
Omat AR film (Eastman Kodak Co., Rochester, NY, USA)
with image intensifying screens. Membranes were then
rehybridized with radiolabeled glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) cDNA (ATCC, pHcGAP) to
provide an internal standard of the amount of RNA load.
Densitometric analysis was performed by scanning the blot
on a Desk Scan II (Hewlett Packard, Comos, WV, USA)
and then analyzed using Imagequant (Molecular Dynamics,
Sunnyvale, CA, USA).
CD 89 mRNA expression by Northern blotting and
RT-PCR and protein expression by flow cytometry
Messangial cells were cultured and prepared as de-
scribed for c-jun Northern blotting except RNA was iso-
lated 24 and 48 hours after the addition of the IgA for assay
of CD 89 mRNA. Hybridization was performed using an
800 base pair fragment of FcaR cDNA from U937 cells,
kindly provided by Dr. C.R. Maliszewski (Immunex, Seat-
tle, WA, USA). For a positive control, U937 cells in
suspension were exposed to PMA 5 ng/ml overnight prior
to isolation of RNA. Reverse transcription-polymerase
chain reaction (RT-PCR) was performed on total cellular
RNA using an RT-PCR kit (Perkin Elmer Cetus, Branch-
burg, NJ, USA). First strand cDNA was synthesized using
murine leukemia virus reverse transcriptase and oligo(dT)
as the primer. Reverse transcription was performed at 42°C
for 60 minutes. cDNA was amplified using the following 59
and 39 primers based on the sequence data for U937 FcaR
cDNA [14] 59-AAGCTTACCTGACCCAGCTGATG-39
and 59-AAGCTTCTTAGTGAGCTTTTCTCTC-39. The
anticipated product contains 701 bases of the translated
region and 96 bases of the untranslated 39 region of FcaR
cDNA, for a predicted size of 797 base pairs. PCR was
performed in a DNA thermal cycler (Perkin Elmer Cetus)
using 94°C melting, 58°C annealing, 72°C extension tem-
perature and 35 cycles according to manufacturer’s instruc-
tions.
Flow cytometry was performed on HMC grown in 10%
FCS and U937 cells stimulated for 24 hours with 5 mM
PMA. Cells were incubated with 2.5 mM EDTA in PBS for
20 minutes and gently scraped from the flask. The samples
were suspended in 0.05 ml PBS with 0.1% BSA and 0.05%
sodium azide at 4°C. The cells were incubated for 30
minutes with 0.05 ml of My 43 culture supernatant (mouse
monoclonal IgM to CD 89; kindly provided by Li Shen,
Dartmouth Medical School, Hanover, NH, USA) in cell
media, washed and incubated 30 minutes with FITC-
labeled goat anti-mouse IgG(H1L) (Accurate, Westbury,
NY, USA). Control cells were treated only with the second
antibody. Cells were then fixed with paraformaldehyde and
analysis was performed on a Becton-Dickenson Model
FACScan (San Jose, CA, USA).
RESULTS
Binding of 125I-IgA1 to human mesangial cells
Equilibrium binding studies were performed to deter-
mine the characteristics of IgA1 binding to the cultured
mesangial cells. Monomeric and aggregated 125I-IgA1
bound to our HMCs in a dose dependent manner and was
saturable at approximately 2 mM or 400 rmoles of IgA1 per
0.2 ml (Fig. 1). Quantitation of IgA1 binding to HMCs (Fig.
1, inset) was performed according to the method of Scat-
chard [35]. The first-order linear regression fit for the
Scatchard plot suggests there is a single population of IgA
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receptors. There are ;1.2 3 106 binding sites per cell with
an affinity constant (Ka) for IgA of 2.3 3 10
6 M21 corre-
sponding to a dissociation constant, Kd, of 4.4 3 10
27 M.
The affinity of these IgA receptors for monomeric IgA or
AIgA were similar based on comparable abilities of either
nonlabled protein to compete for 125I-IgA1 binding (not
shown). ASOR did not inhibit binding of 125I-mIgA1 or
125I-AIgA1 (not shown).
Induction of c-jun by different molecular forms of IgA1
The ability of purified normal IgA1 to induce c-jun
expression in serum-starved HMC was initially examined
using total serum IgA1 (tIgA1). Basal c-jun expression was
determined after 48 hours of serum starvation and incuba-
tion for 60 minutes with protein-free media. Addition of
tIgA1 produced a dose dependent increase in c-jun expres-
sion in HMC (Fig. 2). c-jun expression at 60 minutes was
increased 1.7-fold after addition of 100 mg/ml of tIgA1 and
by twofold over baseline at 200 mg/ml of tIgA1. Expression
of c-jun, relative to GAPDH, was similar for control (media
alone), albumin (250 mg/ml) and tIgA1 (10 mg/ml). At-
tempts to determine which molecular sizes of IgA were
responsible for induction of c-jun revealed that the mIgA1
fraction did not induce the gene (see below). Some prep-
arations of dimeric IgA1 (dIgA1) induced c-jun expression,
but this was not a consistent finding. Recovery of higher
molecular weight fractions of serum IgA1 was not adequate
to assess its inductive activity. Thus, heat aggregated IgA1
was prepared from mIgA1 as a surrogate for naturally
aggregated, higher polymeric forms or immune complexes
containing IgA1.
The ability of mIgA1 and AIgA1, prepared from the same
mIgA1 to induce c-jun gene expression in HMC was
compared. Figure 3A and B are representative Northern
blots that demonstrate a dose response of c-jun induction
by AIgA1. Figure 3C shows the results of a densitometric
analysis of c-jun expression relative to GAPDH in Figure
3B. Expression of c-jun, relative to GAPDH, by HMC
exposed to AIgA1 (10 mg/ml) and albumin (500 mg/ml) was
similar to constituative c-jun expression after 48 hours of
serum starvation (Fig. 3A). Densitometric analysis (Fig.
3C) revealed a 1.5-fold increase in expression at 100 mg/ml,
a 2.9-fold increase at 200 mg/ml, and a 3.8-fold increase at
1000 mg/ml of AIgA1 above baseline expression. Five
experiments using 200 mg/ml of AIgA1 resulted in a 2.43 6
0.57-fold (mean 6 SD) increase in c-jun expression. Thus, a
dose of 200 mg/ml of AIgA1 was used in the remainder of
the experiments.
Exposing HMC to increasing concentrations of the
mIgA1 that was used to prepare AIgA1 had no effect on
c-jun expression. Figure 4A and B display a representative
Northern blot and its densitometric analysis respectively of
Fig. 1. IgA1 binding to human mesangial cells
(HMC). Equilibrium binding of 125I-mIgA1 to
cultured HMCs was assessed at 4°C as
described in the Methods section. Specific
binding was approximately 63%. Figure 1 is the
binding isotherm, and the inset is a Scatchard
plot.
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c-jun expression, relative to GAPDH, following exposure of
HMC for 60 minutes to increasing concentrations of
mIgA1. No induction was noted. Densitometric analysis of
five experiments using 200 mg/ml of mIgA1 revealed no
measurable effect on c-jun expression in HMC [1.04 6
0.21-fold (mean 6 SD) change from c-jun expression of the
controls].
A time course of c-jun expression after addition of 200
mg/ml of AIgA1 is shown in Fig. 5 A and B. A measurable
rise in c-jun was seen at 30 minutes (2.5-fold increase),
peaking at 60 minutes (3.2-fold increase) and returning to
baseline at 120 minutes. This time course is typical of an
immediate early gene response.
CD 89 expression in HMC
To determine the role of the FcaR1 (CD89), in AIgA1-
induced c-jun gene expression in HMC, we examined its
expression using northern analysis, RT-PCR and flow
cytometry. An 800 base pair cDNA fragment of the trans-
lated region of CD 89 was used to probe numerous
Northern blots of total RNA isolated from HMC treated in
several ways. HMC were starved of serum for 24 hours
(time 0) and then incubated with 200 mg/ml of AIgA1 or
mIgA1 for 24 and 48 hours. There was no detectable
constituitive expression, observed at time 0, of mRNA
encoding CD 89 or induction of the gene expression by
AIgA1 (Fig. 6) or mIgA1 (not shown). The experiment was
repeated four times with the 48 hours incubation period
and one time after a short-term (60 min) incubation with
AIgA1. No evidence for mRNA encoding CD 89 in HMC
was demonstrated at either time. Control RNA from U937
cells produced an intense band with the CD 89 probe even
when the total RNA loaded was less than that for HMC
(Fig. 6). The results were consistently negative despite
varying the stringency of the washes and autoradiography
exposure times of the radiolabeled blots. The qualilty of the
HMC mRNA on each blot was indicated by intense label-
ing of GAPDH mRNA.
To determined if the mRNA encoding FcaR1 was
present in HMC at such low copy number that it was not
detectable by Northern analysis, total RNA from HMC,
incubated 0, 24 and 48 hours with 200 mg/ml of AIgA1, was
analyzed by RT-PCR. Using the primers for CD 89 (Meth-
ods section) an intensely staining PCR product of the
Fig. 2. Effect of serum IgA1 on c-jun expression in human mesangial cells. (A) Representative Northern blot of RNA isolated from serum-starved
HMC exposed to media alone (C), albumin (250 mg/ml) and tIgA1 (10, 100, & 200 mg/ml) for 60 minutes. Blots were hybridized with [
32P] c-jun and
GAPDH cDNA. (B) Densitometric analysis of c-jun mRNA levels as a ratio to that of GAPDH. The experiment was performed twice.
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expected size was seen using RNA isolated from U937 cells
as template (Fig. 7). No bands of this size were seen when
any of the mesangial cell mRNA samples were tested.
b-Actin, which served as a positive control to ensure the
integrity of the reverse transcriptase product from the RNA
isolated from HMC, produced an intense band of expected
size (not shown). RT-PCR of HMC mRNA, using the same
primers was repeated five times and two times using the
primers described by Bagheri, Chintalacharuvu and Eman-
cipator [13] with the same result.
To confirm that long-lived FcaR1 protein was not
present on the surface of HMC, we used flow cytometry to
examine the binding to cultured HMC of My 43, a mono-
clonal IgM antibody to FcaR1. No binding of My 43 was
detected in HMC, while My 43 binding to U937 was clearly
demonstrated (Fig. 8).
DISCUSSION
In IgAN polymeric IgA1 deposits in the glomerular
mesangium in proximity to mesangial cells [3, 4] and may
be responsible, in part, for the characteristic histologic
changes seen in renal biopsies. The binding of IgA to the
mesangial cells might induce in vivo proliferation and
deposition of excess matrix as has been demonstrated in
mouse models of IgA immune complex nephritis [11, 36].
Although there is co-deposition of other serum proteins,
IgA is the predominant immune reactant seen in human
IgAN, and in the absence of an influx of inflammatory cells
it is likely that the interaction of pIgA with the mesangial
cell may initiate the pathologic changes. In fact, injection of
mouse IgA anti-Thy 1.1 antibody, which binds to mesangial
cells, into mice results in hematuria without producing an
Fig. 3. Effect of AIgA1 on c-jun expression in human mesangial cells. (A) Representative Northern blot of total RNA isolated form serum-starved HMC
exposed to media alone (C), albumin (500 mg/ml) and AIgA1 (10, 100, and 200 mg/ml) for 60 minutes. (B) Representative Northern blot of total RNA
isolated form serum-starved HMC exposed to AIgA1 [10, 100, 200, and 1000 mg/ml] for 60 minutes. Blots were hybridized with [
32P] c-jun and GAPDH.
(C) Densitometric analysis of c-jun mRNA levels, from (B), as a ratio to GAPDH.
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inflammatory response [37]. Previous investigations have
shown that incubation of cultured mesangial cells with IgA
induces intracellular signaling events (such as, calcium flux)
and up-regulates FcaR1 gene expression and inflammatory
cytokine secretion [12, 13, 19, 22, 23]. In some of these
studies, mesangial cell responses to IgA1 were thought to
be mediated through FcaR1 (CD 89) [12, 13, 23], but this
proposition has not been confirmed by inhibition studies
using antibodies to FcaR1.
In the current study, the expression of an immediate
early gene was chosen as a marker for cell activation as it is
one of the earliest nuclear events in cell stimulation and is
associated with various cellular responses. Although c-jun
expression has not been directly correlated with a specific
cellular event in HMC, in other cells up-regulation of c-jun
often occurs prior to proliferation and enhanced synthesis
of numerous mRNAs and proteins.
Our initial studies reveal that normal serum IgA1 acti-
vates mesangial cells in vitro as measured by c-jun induc-
tion. Comparison of the three molecular forms (mIgA1,
dIgA1 and pIgA1) of serum IgA1 suggested that the higher
molecular weight forms were responsible for activation, as
mIgA1 did not induce c-jun expression. Whether dIgA1,
higher molecular weight polymers of IgA1 or combination
of the two fractions was responsible for activation could
not be determined, since induction of c-jun was not consis-
tently seen with the concentration of these fractions avail-
able for study. Therefore, heat aggregated IgA1 was used as
a substitute for the higher molecular weight forms of serum
IgA, particularly the polymeric form [12, 23, 29]. We found
that AIgA1 did induce c-jun expression with the typical
time course for immediate early gene expression and was
dose dependent up to 1,000 mg/ml of AIgA. Whether this is
a saturable process was not determined, but the highest
concentrations tested probably exceed that of polymeric
IgA1 present in serum even from IgAN patients. In con-
trast, mIgA1 had no effect on c-jun expression in HMC
despite exposure to molar concentrations that were higher
than those used for AIgA1. The induction of c-jun expres-
sion by AIgA1 was not due to variation in IgA structures or
contamination with other serum proteins or exogenous
endotoxin since the aggregates were prepared from the
same preparations of monomeric IgA1 and their effects
compared directly. The induction of c- jun was not due to
a difference in osmolality of the final solutions of mIgA1
and AIgA1, as the osmolalities ranged from 305 to 309
mOsm.
These findings suggest the biologic response of HMC to
IgA1 is dependent on the higher molecular weight forms of
IgA1. This is not a unique finding, as inflammatory cells
Fig. 4. Effect of monomeric IgA1 on c-jun expression in human mesangial cells. (A) Representative Northern blot of total RNA isolated from serum
starved HMC exposed to media alone (C) and mIgA1 (10, 100, 200 and 1,000 mg/ml) for 60 minutes. Blots were hybridized with [
32P] c-jun and GAPDH
cDNA. (B) Densitometric analysis of c-jun mRNA levels as a ratio to that of GAPDH.
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with IgA receptors often require polymers of IgA or
cross-linking of monomers for cell activation [38, 39]. In
addition, this concept is consistent with the increased
amounts of IgA polymers seen in some IgAN patients [6]
and the finding that IgA deposits in biopsy specimens of
IgAN patients contain predominantly higher molecular
weight forms [9].
Since linkage between mesangial cells expression of
Fig. 5. Time course of c-jun expression in human mesangial cells in the presence of aggregated IgA1. (A) Northern blot of total RNA isolated form
serum starved HMC at 0, 30, 60, 90 and 120 minutes in the presence of AIgA1 (200 mg/ml). Blots were hybridized with [
32P] c-jun and GAPDH cDNAs.
(B) Densitometric analysis of c-jun mRNA levels relative to that of GAPDH.
Fig. 6. Fca receptor (CD 89) expression in
human mesangial cells. Representative
Northern blot of total RNA isolated from
serum starved HMC exposed to AIgA1 (200
mg/ml) for 0, 24 and 48 hours (lanes 1 to 3).
Total RNA was isolated from U937 cells
exposed to PMA for 24 hours (lane 4). Blots
were hybridized with [32p] FcaR and GAPDH
cDNA.
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FcaR1 (CD 89) and a number of functional events follow-
ing exposure to IgA has been suggested, we attempted to
determine if c-jun induction in our cells was mediated
through that receptor. However, we could find no evidence
that CD 89 was expressed in cultured human mesangial
cells used in our studies. Constitutive expression of CD 89
mRNA was not detected by Northern analysis and the
mRNA was not induced by exposing the cells to various
concentrations of mIgA1 or AIgA1. To exclude the possi-
bility of low mRNA copy number and/or slow receptor
protein turnover at the cell surface, we performed RT-PCR
using two different sets of primers for CD 89. While the
expected PCR product for CD 89 was easily demonstrated
using mRNA from U937 cells, no similarly sized transcript
was amplified in quiescent or IgA1-stimulated HMC and no
staining with an antibody specific for CD 89 was detectable
on these cultured mesangial cells.
One possible explanation for the lack of CD 89 expres-
sion in the cells is that it is lost after multiple passages. We
therefore examined cells at passages 3 and 4 and were
unable to find mRNA for CD 89. These data are in contrast
to that reported by Gomez-Guerrero, Gonzalez and Egido
[12] and Bagheri et al [13], who demonstrated the presence
of CD 89 mRNA by Northern analysis and RT-PCR in
quiescent and IgA-exposed primary or early passage mes-
angial cells. One possible explanation for this difference is
that primary cultures of mesangial cells, grown from glo-
merular explants, which the first group studied, are often
contaminated with resident macrophages [12]. We did not
test our cells at zero passage for effect of IgA on c-jun
expression or the presence of CD 89. Differences in
techniques, including culture media, are also possible but
unlikely explanations for the different experimental results.
Thus, while our studies cannot exclude the possibility that
FcaR1 is expressed by mesangial cells in vivo or very early
in culture, our results suggest that there are other mecha-
nisms by which IgA can bind to and activate human
mesangial cells.
Several other membrane receptors are known to bind
IgA. It is unlikely that IgA1 bound to HMC via the
polymeric immunoglobulin receptor (pIgR) since our ra-
diolabeled mIgA1 preparations, which were free of poly-
meric IgA bound to HMC. ASOR, an excellent ligand for
the asialoglycoprotein receptor, did not compete for mIgA1
or AIgA1 binding to the mesangial cells, effectively elimi-
nating the possibility that IgA1 binds via this receptor.
Thus, the receptor for IgA1 in our cells does not correspond
to any of the previously characterized IgA receptors.
The binding characteristics of IgA1 to human mesangial
cells in this study are comparable to those reported by
Bagheri et al [13], though the number of binding sites per
cell is higher and the affinity lower by approximately one
log. In addition, our binding data for affinity and the
number of binding sites per cell are within the range
Fig. 7. Fca receptor (CD 89) mRNA
expression in human mesangial cells treated
with monomeric IgA1 and AIgA1. Total RNA
was isolated from serum starved HMC
following timed exposure to 200 mg/ml of
mIgA1 (lanes 1 to 3) and AIgA1 (lanes 4 to 6),
reverse transcribed and PCR amplified for
FcaR. Total RNA from PMA stimulated U937
cells served as a positive control (lane 7). PCR
products were separated in 3% agarose gel and
stained with ethidium bromide.
Diven et al: IgA activation of mesangial cell 845
reported for rat mesangial cells [12, 22]. In all cases the
slope of the Scatchard plots suggest a single population of
receptors. However, a similarity in affinity between FcaR1
and another IgA receptor would have made it difficult to
determine in previous studies if two different receptor
populations (iso-receptors) were expressed on the same
population of cells. It is likely that an IgA receptor distinct
from CD 89 is present in our mesangial cells. However, the
identity, specificity and function of this receptor are as yet
unknown.
Since our studies employed serum polyclonal IgA as the
ligand, the possibility that this IgA contains antibodies that
bind to mesangial cells cannot be excluded. Interestingly, a
study using a monoclonal IgA isotype switch variant of
anti-Thy 1.1 antibody, which binds to mesangial cells, was
administered to rats and induced hematuria without evi-
dence of infiltration of inflammatory cells [37] typically
seen when IgG anti-Thy 1.1 is administered. Thus, the type
of local response to ligation of Thy 1.1 on mesangial cells
was less dependent on the receptor per se, than the class of
antibody and was seen with dimeric and polymeric IgA.
This suggests crosslinking of mesangial cell membrane
proteins may be an important component of the local
response. Rapid uptake and degradation of mIgA and
AIgA in inflammatory and mesangial cells has been de-
scribed [19, 39], and raises the possibility of second mes-
senger activation of the cell. Platelet-derived growth factor
(PDGF) and transforming growth factor-b (TGF-b) are
synthesized by human mesangial cells and can act in an
autocrine or paracrine fashion resulting in cell proliferation
and/or matrix synthesis [40]. Studies of IgAN patient biopsy
samples by in situ hybridization have revealed increased
expression of TGF-b and PDGF compared with normals
and disease controls [41]. Thus, either factor may have a
role as a second messenger in IgA induced c-jun induction.
Our results demonstrate that while mesangial cells bind
both monomeric and aggregated IgA with similar affinity,
activation of mesangial cells by IgA1 is dependent on the
aggregate form, which is a model of polymeric IgA. Previ-
ous reports also support the concept that aggregates of IgA
are necessary for cell activation [22, 39]. We also confirmed
that the cells bind IgA1 within the range of kinetics
previously reported. However, the mechanism of interac-
tion between the mesangial cell and IgA1 was not deter-
mined, since expression of FcaR1 (CD 89) does not appear
to explain the effect of IgA on our cells. This suggests that
a different receptor or other cell surface mechanism may be
responsible for the cellular events induced in mesangial
cells by IgA.
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APPENDIX
Abbreviations used in this article are: AIgA1, heat aggregated IgA1;
ASOR, asialo orosomucoid; CD89, FcaR1; dIgA1, dimeric IgA1; DMEM,
Dulbecco’s modified Eagle’s medium; FCS, fetal calf serum; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; HBSS, Hank’s balanced salt
solution; HMC, human mesangial cells; HPLC, high-pressure liquid
chromatography; IgAN, IgA nephropathy; IL, interleukin; IP3, inositol
phosphate 3; Ka, affinity constant; Kd, dissociation constant; mIGA1,
monomeric IGA1; PAF, platelet activating factor; PBS, phosphate buff-
ered saline; PGE2, prostaglandin E2; pIgA1, polymeric IgA1; pIgR,
polymeric immunoglobulin receptor; PLCg3, phospholipase Cg3; RT-
PCR, reverse transcription-polymerase chain reaction; SC, secretory
component; tIgA1, total IgA1; TNF-a, tumor necrosis factor-a.
Fig. 8. CD 89 expression on human mesangial cells. Flow cytometric scan
of the distribution of cell frequencies for cells treated with My 43 (open),
a CD 89 specific monoclonal antibody, and fluorescence-labeled second-
ary antibody only (filled). Panel (A) U937 cells and panel (B) HMC.
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